A Phase 3 interventional study of CT-P17 SC AI (adalimumab) in Rheumatoid Arthritis, sponsored by Celltrion. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by Celltrion · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 67th largest by enrollment, is one of 4 that started in 2019, is one of 36 in phase 3, and was the 81st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
15 studies in Arthritis, Rheumatoid by Celltrion: none open now, 1 under way, none of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 15 studies in Arthritis, Rheumatoid by Celltrion, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 10 in phase 3, and was the 10th registered.
Celltrion’s Arthritis, Rheumatoid studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Celltrion’s 15 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal antibody that is being developed as a similar biological medicinal product to Humira. The purpose of this study is to evaluate usability of subcutaneous auto-injector of CT-P17 in patients with moderate to severe rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)
Biological: CT-P17 SC AI (adalimumab)
Subcutaneous Injection of Adalimumab 40mg once every two weeks
The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4
The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). \[Scores were transformed to Rate between 0 (worst) to 10 (best)\]
Time frame: Week 4
Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
Time frame: Week 0
Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24
Time frame: Week 0,2,4,24
Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)
DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate
Time frame: Week 8,16,24
Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
Time frame: Week 2
Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
Time frame: Week 24
| Milestone | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Started | 62 |
| Completed | 60 |
| Not completed | 2 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 1 |
The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). \[Scores were transformed to Rate between 0 (worst) to 10 (best)\]
| scores on a scale | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Feelings about self-injections (PRE) | 8.00 ± 2.131 |
| Feelings about self-injections (POST) | 8.16 ± 2.036 |
| Self-confidence (PRE) | 6.55 ± 1.859 |
| Self-confidence (POST) | 7.07 ± 1.616 |
| Self-image (POST) | 8.39 ± 2.079 |
| Pain and skin reactions during or after the injection (POST) | 9.59 ± 0.968 |
| Ease of use of the self-injection device (POST) | 8.70 ± 1.457 |
| Satisfaction with self-injection (PRE) | 8.27 ± 1.669 |
| Satisfaction with self-injection (POST) | 8.23 ± 1.191 |
| scores on a scale | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Feelings about self-injections (PRE) | 7.39 ± 2.437 |
| Feelings about self-injections (POST) | 8.04 ± 2.086 |
| Self-confidence (PRE) | 5.22 ± 2.272 |
| Self-confidence (POST) | 6.18 ± 2.518 |
| Self-image (POST) | 8.35 ± 2.306 |
| Pain and skin reactions during or after the injection (POST) | 9.48 ± 1.152 |
| Ease of use of the self-injection device (POST) | 8.40 ± 1.531 |
| Satisfaction with self-injection (PRE) | 6.15 ± 1.682 |
| Satisfaction with self-injection (POST) | 8.00 ± 1.250 |
| Participants | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Week 0, Successful Self-Injection | 62 |
| Week 0, Overall Successful Self-Injection | 62 |
| Week 2, Successful Self-Injection | 62 |
| Week 2, Overall Successful Self-Injection | 62 |
| Week 4, Successful Self-Injection | 62 |
| Week 4, Overall Successful Self-Injection | 62 |
| Week 24, Successful Self-Injection | 60 |
| Week 24, Overall Successful Self-Injection | 60 |
DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate
| scores on a scale | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| CRP, Baseline | 5.248 ± 0.8415 |
| CRP, Week 8, Change from baseline | -2.560 ± 1.1223 |
| CRP, Week 16, Change from baseline | -2.795 ± 1.2381 |
| CRP, Week 24, Change from baseline | -3.111 ± 1.1109 |
| ESR, Baseline | 6.190 ± 0.7360 |
| ESR, Week 8, Change from baseline | -3.287 ± 1.3525 |
| ESR, Week 16, Change from baseline | -3.495 ± 1.4695 |
| ESR, Week 24, Change from baseline | -3.799 ± 1.4287 |
| scores on a scale | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Feelings about self-injections (PRE) | 7.93 ± 2.175 |
| Feelings about self-injections (POST) | 8.08 ± 2.110 |
| Self-confidence (PRE) | 6.61 ± 2.007 |
| Self-confidence (POST) | 6.67 ± 1.811 |
| Self-image (POST) | 8.27 ± 2.245 |
| Pain and skin reactions during or after the injection (POST) | 9.64 ± 0.693 |
| Ease of use of the self-injection device (POST) | 8.34 ± 1.698 |
| Satisfaction with self-injection (PRE) | 7.78 ± 2.128 |
| Satisfaction with self-injection (POST) | 8.16 ± 1.177 |
| scores on a scale | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Feelings about self-injections (PRE) | 8.88 ± 2.034 |
| Feelings about self-injections (POST) | 8.97 ± 1.888 |
| Self-confidence (PRE) | 7.21 ± 1.556 |
| Self-confidence (POST) | 7.44 ± 1.840 |
| Self-image (POST) | 9.04 ± 1.533 |
| Pain and skin reactions during or after the injection (POST) | 9.60 ± 0.841 |
| Ease of use of the self-injection device (POST) | 9.35 ± 1.057 |
| Satisfaction with self-injection (PRE) | 8.83 ± 1.868 |
| Satisfaction with self-injection (POST) | 8.95 ± 1.023 |
Collected over Adverse events were assessed from the date the patient signed the ICF until EOS/ED visit. (up to week 28, including 4 weeks of follow-up period). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| "CT-P17 SC AI (Adalimumab)" | 1/62 (1.6%) | 3/62 (4.8%) | 20/62 (32.3%) |
| Event | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/62 |
| Tooth infectionInfections and infestations | 1/62 |
| Cervical polypReproductive system and breast disorders | 1/62 |
| Event | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/62 |
| Urinary tract infectionInfections and infestations | 3/62 |
| DiarrhoeaGastrointestinal disorders | 2/62 |
| HeadacheNervous system disorders | 2/62 |
| HyperbilirubinaemiaHepatobiliary disorders | 2/62 |
| Influenza like illnessGeneral disorders | 2/62 |
| Injection site reactionGeneral disorders | 2/62 |
| NasopharyngitisInfections and infestations | 2/62 |
| PharyngitisInfections and infestations | 2/62 |
| Age, Categorical(Participants) | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 56 |
| >=65 years | 6 |
| Age, Continuous(Years) | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Median | 54.0 (19 to 70) |
| Sex: Female, Male(Participants) | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Female | 42 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 62 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 62 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | "CT-P17 SC AI (Adalimumab)" |
|---|---|
| Poland | 62 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Nov 2019, 1 month.
Results were first posted in Nov 2021, 2 years after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 1 month is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab